Hyloris Pharmaceuticals S.A.
HYL.BR · BRU
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | €0 | €0 | €0 | €0 |
| - Cash | €0 | €0 | €0 | €0 |
| + Debt | €0 | €0 | €0 | €0 |
| Enterprise Value | €0 | €0 | €0 | €0 |
| Revenue | €0 | €0 | €0 | €0 |
| % Growth | 381.2% | -29.3% | -4.7% | – |
| Gross Profit | €0 | €0 | €0 | €0 |
| % Margin | 97.7% | 95.5% | 96.8% | 96.5% |
| EBITDA | -€0 | -€0 | -€0 | -€0 |
| % Margin | -48.3% | -717.8% | -387.4% | -348.2% |
| Net Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | -63.2% | -736.9% | -403.5% | -374% |
| EPS Diluted | -0.22 | -0.55 | -0.44 | -0.45 |
| % Growth | 60% | -25% | 2.2% | – |
| Operating Cash Flow | -€0 | -€0 | -€0 | -€0 |
| Capital Expenditures | -€0 | -€0 | -€0 | -€0 |
| Free Cash Flow | -€0 | -€0 | -€0 | -€0 |